{
  "id": "fda_guidance_chunk_0722",
  "title": "Introduction - Part 722",
  "text": "and humidity, distribution of used litter across treatment groups, used or new litter, etc. 8.13 Provisions for necropsy and disposal of expired test subjects 8.14 Owner Consent (if applicable) 9 SPECIFICATION OF VARIABLES: 9.1 Variable(s) to be measured for evaluating labeled claim: 9.1.1 When variable(s) will be assessed 9.1.2 Procedures for assessing variable 9.1.3 Equipment used to assess variable 9.1.4 Calculation of derived data 9.1.5 Forms for retention of source data 9.1.6 Name(s) and address(es) of outside labs used for analysis 9.2 Other variables to be recorded during the study: 9.2.1 When variable(s) will be assessed 9.2.2 Procedures for assessing variable 9.2.3 Equipment used to assess variable 9.2.4 Calculation of derived data 10 DATA ANALYSIS (Depends upon protocol design chosen and the variables measured. Details of the analysis procedure should be provided) 10.1 Define the experimental unit 10.2 Define the number of replicates per treatment 10.3 Define statistical methodology, including hypothesis to be tested or parameters to be estimated, assumptions that are being made, and model specification if a model is to be used. 10.4 Define how the statistical results will be used to draw conclusions about the study's objectives 11 STUDY LOCATION(S): 12 PERSONNEL: (Provide debarment statements) 12.1 Investigator(s): 12.1.1 Address 12.1.2 Telephone number 12.1.3 Training and experience of investigator (prefer CVs) 12.2. Study Monitor: 12.2.1 Address 12.2.2 Telephone number 12.2.3 Training and experience of monitor (prefer CVs) 12.3 Consultants (pathologist, statistician, etc.): 12.3.1 Address 12.3.2 Telephone number 12.3.3 Training and experience of each consultant (prefer CVs) 12.4 Quality Assurance Unit: 12.4.1 Address 12.4.2 Telephone number 12.5 Other personnel involved in study: 12.5.1 Address 12.5.2 Telephone number 12.5.3 Involvement in study 12.5.4 Training and experience of other personnel (prefer CVs) 13 COLLECTION AND RETENTION OF SOURCE DATA: 14 ADDENDUM/DEVIATIONS TO THE PROTOCOL: 15 INVESTIGATIONAL DRUG AND CONTROL: 15.1 Test Substance(s): 15.1.1 Chemical name 15.1.2 Trade name 15.1.3 Active/inactive ingredients (is this the final formula?) 15.1.4 Dosage form (solution, powder, granules, etc.) 15.1.5 Dose(s) to be tested (mg/gram, mg/mL, etc.) 15.1.6 Manufacturing site (name and address) 15.1.7 Lot No. 15.1.8 Packaging 15.1.9 Drug storage during study (define storage environment and drug's stability characteristics in the proposed storage environment) 15.1.10 Material Safety Data Sheet (MSDS) 15.2 Control (placebo, vehicle, positive control, etc.) Identification of applicable items from 11.1 16 DRUG DISPOSITION/ANIMAL ACCOUNTABILITY/FEED DISPOSITION/FEED ACCOUNTABILITY: The",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 969024,
  "end_pos": 970560,
  "tokens": 512,
  "tags": [
    "safety",
    "design",
    "statistical",
    "clinical_trial",
    "consent",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "guidance",
  "created_at": "2025-10-23T02:25:44.733Z"
}